{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:30Z","timestamp":1783908510672,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1009"],"award-info":[{"award-number":["23FC1009"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05274-0","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:51:27Z","timestamp":1774932687000},"page":"14581-14585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis"],"prefix":"10.1007","volume":"399","author":[{"given":"Manato","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Ogaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kurumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Takasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"1","key":"5274_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1607","volume":"3","author":"JT Andersen","year":"2012","unstructured":"Andersen JT, Dalhus B, Cameron J et al (2012) Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun 3(1):610. https:\/\/doi.org\/10.1038\/ncomms1607","journal-title":"Nat Commun"},{"issue":"5","key":"5274_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"issue":"3","key":"5274_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","volume":"186","author":"M Goebeler","year":"2022","unstructured":"Goebeler M, Bata-Cs\u00f6rg\u0151 Z, De Simone C et al (2022) Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol 186(3):429\u2013439. https:\/\/doi.org\/10.1111\/bjd.20782","journal-title":"Br J Dermatol"},{"key":"5274_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"5274_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.176166","volume":"9","author":"G Ma","year":"2024","unstructured":"Ma G, Crowley AR, Heyndrickx L et al (2024) Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin. JCI Insight 9:e176166. https:\/\/doi.org\/10.1172\/jci.insight.176166","journal-title":"JCI Insight"},{"key":"5274_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga AR, Maddison P, Heckmann JM et al (2022) Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 21:176\u2013188. https:\/\/doi.org\/10.1016\/s1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"issue":"7","key":"5274_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS (2023) The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 23(7):415\u2013432. https:\/\/doi.org\/10.1038\/s41577-022-00821-1","journal-title":"Nat Rev Immunol"},{"key":"5274_CR8","doi-asserted-by":"publisher","unstructured":"Smith B, Kiessling A, Lledo-Garcia R et al (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. mAbs 10:1111\u20131130. https:\/\/doi.org\/10.1080\/19420862.2018.1505423","DOI":"10.1080\/19420862.2018.1505423"},{"key":"5274_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534","volume":"13","author":"ES Ward","year":"2022","unstructured":"Ward ES, Gelinas D, Dreesen E et al (2022) Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders. Front Immunol 13:892534. https:\/\/doi.org\/10.3389\/fimmu.2022.892534","journal-title":"Front Immunol"},{"issue":"7","key":"5274_CR10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP et al (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487. https:\/\/doi.org\/10.1212\/wnl.52.7.1487","journal-title":"Neurology"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05274-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:43:25Z","timestamp":1783907005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05274-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5274"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05274-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The street address for Department of Neurology, Graduate School of Medicine, Chiba University was unexpectedly duplicated as \"1-8-1 1-8-1.\"","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for written informed consent was waived by the Ethics Committees of the Chiba University School of Medicine (IRB No. 2266). All participants were provided the opportunity to opt-out of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was conducted in accordance with the 1964 Helsinki Declaration and its later amendments. The study was approved by the Ethics Committees of the Chiba University School of Medicine (IRB No. 2266).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"M. Yasuda received honoraria from Alexion Pharmaceuticals, Argenx, UCB, Asahi Kasei Medical, and Japan Blood Products Organization.\u00a0A. Uzawa received honoraria from Alexion Pharmaceuticals, Argenx, Novartis, Chugai Pharmaceutical, and UCB. H. Handa received honoraria from Argenx and Chugai Pharmaceutical. K. Kurumada received honoraria from Alexion Pharmaceuticals. M. Mori received honoraria from Alexion Pharmaceuticals, Novartis, Chugai Pharmaceutical, and Mitsubishi Tanabe Pharma, and Biogen. S. Kuwabara received honoraria from Argenx and CSL Behring. E. Ogaya and K. Takasaka declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}